# Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease

> **NCT00558337** · PHASE2 · COMPLETED · sponsor: **Osmotica Pharmaceutical US LLC** · enrollment: 78 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** levodopa-carbidopa

## Key facts

- **NCT ID:** NCT00558337
- **Lead sponsor:** Osmotica Pharmaceutical US LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2009-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558337, "Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00558337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*